Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Simcere Pharmaceutical have partnered to form a joint venture (JV) with an aim to offer medicines targeting significant therapeutic segments in China.
Subscribe to our email newsletter
Initially, the partnership will be focused on branded pharmaceutical products for cardiovascular and metabolic diseases.
Under the deal, both the parties will offer combined portfolio of drugs for cardiovascular disease which include Merck’s ZOCOR (simvastatin), COZAAR (losartan) and RENITEC (enalapril) and Simcere’s XINTA (levamlodipine) and SHUFUTAN (rosuvastatin).
Additionally, in metabolic field, the tie up aims to maximize the access of sitagliptin drug as a treatment of type 2 diabetes.